Acadia's Nuplazid flops schizophrenia trial on the heels of DOJ marketing probe

23rd July 2019 Uncategorised 0

Acadia’s controversial antipsychosis med Nuplazid faced its share of scrutiny after a safety controversy drew federal eyeballs in March. Now, the drug has flopped a trial in schizophrenia, throwing a spanner into its pursuit of a first-ever adjunct approval.

More: Acadia's Nuplazid flops schizophrenia trial on the heels of DOJ marketing probe
Source: fierce